Hosted on MSN19h
For Your Patients: What Is Multiple Myeloma?
Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...
emjreviews.com23h
High-Risk Genetic Markers Predict Poor Outcomes in Multiple Myeloma
Study reveals multiple high-risk genetic changes predict worse multiple myeloma outcomes across all treatments.
Medpage Today on MSN1d
The Basics of Multiple Myeloma
In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...
NHS red tape preventing cancer patients from receiving breakthrough treatments
Drugs proven to improve survival rates and that are used in other European countries have been withdrawn owing to cost-effective thresholds ...
Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...
Regeneron Pharmaceuticals, Inc.: Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...
Sioux City Journal6d
Iowa maintains fastest-growing cancer rate, but more survive
With Iowa maintaining the second-highest and fastest-growing rate of new cancers nationally, according to a 2025 Cancer in ...